Prot #ITL-2001-CL-311: MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)